ALNY vs HLIO · P/E 76, rev $1.29B vs P/E 47, rev $460.3M
Alnylam Pharmaceuticals Inc (ALNY) versus Helios Technologies Inc (HLIO) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Helios Technologies Inc (HLIO) is a specialty industrial machinery company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported HLIO revenue for 2026-07-04 was $460.3M. Net income was $41.6M. HLIO currently screens at market cap $2.84B and trailing P/E 47.2.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. HLIO currently screens at market cap $2.84B and trailing P/E 47.2.
Not investment advice. Open the ALNY and HLIO stock pages for the full models.
Not investment advice.